国信证券股份有限公司 关于深圳市沃特新材料股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 国信证券股份有限公司（以下简称"国信证券"、"保荐人"）作为深圳市沃 特新材料股份有限公司（以下简称"沃特股份"、 "公司"）2022 年度向特定对象 发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等有关规定，对公司使用部分闲置募集资金暂时补充流动资金事项 进行了审慎核查，具体核查情况如下： 一、募集资金基本情况 总部基地及合成生物材料创新中 根据中国证券监督管理委员会（以下简称"中国证监会"） 《关于同意深圳市 沃特新材料股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕 总额为人民币 599,999,989.68 元，募集资金净额为人民币 587,852,395.60 元。上 述募集资金已全部到位，中喜会计师事务所（特殊普通合伙）于 2023 年 8 月 11 （中喜验资 2023Y00046 号）。公司对募集资金采取了专户 日出具了《验资报告》 存储制度，开立了募集资金专项账 ...

中信证券股份有限公司关于山东龙大美食股份有限公司 继续使用部分闲置募集资金暂时补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为山东龙 大美食股份有限公司（以下简称"龙大美食"或"公司"）2021 年非公开发行股 票的保荐人，承接龙大美食 2020 年公开发行可转换公司债券的持续督导工作， 法定持续督导期截止至 2022 年 12 月 31 日。因龙大美食的募集资金尚未使用完 毕，保荐人仍需对公司募集资金的使用和管理继续履行督导义务。 根据《证券发行上市保荐业务管理办法（2025 修正）》《上市公司募集资金 监管规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作（2025 年修订）》等有关规定的要求，保荐人对公司继续使用部分闲置募 集资金暂时补充流动资金的情况进行了审慎核查，核查情况及保荐意见如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）证监许可[2020]1077 号文核准，公司于 2020 年 7 月 13 日向社会公众公开发行的可转换公司债券（简 称"龙大转债"，债券代码为"128119"）规模为 95,00 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002407 证券简称：多氟多 公告编号：2025-061 多氟多新材料股份有限公司 第七届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假记载、误导性陈述或者重 大遗漏。 一、董事会会议召开情况 多氟多新材料股份有限公司（以下简称"公司"）第七届董事会第三十一次会议通知于2025年7月27日通 过微信、电子邮件等方式向各董事发出，会议于2025年8月7日上午9：00在焦作市中站区焦克路公司科 技大厦五楼会议室以现场和通讯相结合方式召开。本次会议应出席董事9人，实际出席本次会议的董事 共计9人，会议由董事长李世江先生主持，公司监事和部分高级管理人员列席会议。会议的召开符合 《公司章程》规定的程序，并达到了《公司法》及《公司章程》规定的召开董事会会议的法定表决权 数。 二、董事会会议审议情况 会议以投票表决的方式，审议通过了以下议案： 1、《关于使用部分闲置募集资金暂时补充流动资金并拟在银行开立募集资金临时补流专项账户、授权 签订募集资金三方监管协议的议案》 表决结果：9票赞成，0票反对，0票弃权。 详 ...

当日关注点 截至2025年8月6日收盘，臻镭科技(688270)报收于56.37元，上涨4.54%，换手率4.45%，成交量9.54万 手，成交额5.32亿元。 董秘最新回复 投资者： 贵公司价格一直超当初设定的价格，为什么不肯提高回购价格上限，是对公司发展没信心还 是公司觉得公司估值过高，不肯提高回购价格？现在好多好公司已经提高回购价格了，如果看好公司， 应该提高回购价格，这样才能彰显对自己高速公司发展 董秘： 答：感谢您对公司的关注和建议，公司会予以考虑的，如果有相关计划安排，公司会及时履行 公告义务。 投资者： 请教以下3个问题：截止目前1.除低轨互联网卫星外，公司传统的遥感卫星订单和销售同比或 环比是否有显著的增长？2.十四五收官之年，已披露中报或预告的军工企业，合同负债与军工电子明显 放量，公司军工芯片这块同比是否有显著增长？3.公司三年的愿景展望，如何成为中国的ADI？ 董秘： 答：截止目前，公司在手订单（含口头订单）/在手项目同比呈现明显增长态势，公司将积极做 好生产计划，有序组织排产，确保产品按期交付。 2025年3月28日，公司再次召开会议，审议通过了使用剩余超募资金永久补充流动资金的议案。 ...

Core Viewpoint - The company is utilizing part of the idle funds raised from a non-public offering to temporarily supplement its working capital, which is deemed necessary for operational efficiency and financial management [1][5][6]. Summary by Sections 1. Non-Public Offering Fund Details - In 2017, the company raised a total of RMB 1,306,108,798.84 through a non-public offering of 74,720,183 shares at RMB 17.48 per share, with net proceeds amounting to RMB 1,288,808,798.84 after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized RMB 910,351,700 for various projects, including RMB 224,940,400 for self-funded projects [2][3]. 2. Fund Utilization and Remaining Balance - The company has invested in several projects, with the following actual investment amounts: - Chemical Preparation International Industrialization Project: RMB 545,134,000 - Lianhua Qingwen Capsule International Registration Project: RMB 206,108,800 - Lianhua Qingwen Series Product Capacity Enhancement Project: RMB 254,866,000 - Supplementing Working Capital: RMB 300,000,000 - Total: RMB 1,306,108,800 [3][4]. - As of June 30, 2025, the remaining balance of the non-public offering funds is RMB 50,706,684.42 [4][5]. 3. Temporary Working Capital Supplement - The company plans to use up to RMB 150,000,000 of idle funds to temporarily supplement working capital, with a usage period not exceeding 12 months [5][6]. - The decision is based on the expectation that approximately RMB 150,000,000 will be idle in the Chemical Preparation International Industrialization Project over the next 12 months, aiming to enhance fund utilization efficiency and reduce financial costs [5][6]. 4. Approval and Compliance - The proposal to use idle funds for working capital has been approved by the company's board and is compliant with relevant regulations, ensuring that it does not affect the ongoing projects or shareholder interests [6][7].

Summary of Key Points Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the implementation of its fundraising investment projects [1][4][6]. Group 1: Fundraising Overview - The company raised a total of RMB 894,999,954.16, with a net amount of RMB 875,792,998.29 after deducting related expenses [1][2]. - The funds were raised through the issuance of 96,030,038 shares at a price of RMB 9.32 per share, approved by the China Securities Regulatory Commission on June 26, 2023 [1]. Group 2: Fund Management and Usage - The company has established a fundraising supervision account and signed a tripartite/four-party supervision agreement with the sponsor and relevant banks [2]. - As of July 1, 2025, the company has used RMB 69,363.46 million of the raised funds, leaving RMB 18,985.96 million (including interest and net cash management income) unutilized [2]. Group 3: Temporary Fund Usage - The company plans to use up to RMB 17,500 million of idle funds to temporarily supplement working capital, with a usage period of up to 12 months from the board's approval [4][5]. - This temporary use of funds is expected to save approximately RMB 5.25 million in financial costs based on the current one-year loan market quotation rate of 3% [4]. Group 4: Compliance and Approval - The board and supervisory committee have approved the use of idle funds, confirming that it will not affect the normal progress of fundraising investment projects [6]. - The sponsor has verified that the company's actions comply with relevant regulations and do not change the intended use of the raised funds [6].

Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the normal progress of its fundraising investment projects [6][9]. Group 1: Fundraising Overview - The company was approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with a net amount of RMB 843.209 million after deducting issuance costs [2][3]. - As of the date of the verification opinion, the remaining balance of the raised funds is RMB 192.519 million, including oversubscription funds [6]. Group 2: Fund Utilization - The company has used RMB 496.663 million of the raised funds for third-party medical device logistics construction projects [4]. - The company plans to use up to RMB 92.75 million of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [7][9]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the use of idle funds, ensuring compliance with relevant regulations [9][10]. - The company will open a special account at a bank for the management of these funds and sign a tripartite supervision agreement to oversee the storage and usage of the raised funds [8]. Group 4: Financial Efficiency - By utilizing the idle funds, the company expects to save approximately RMB 2.78 million in financial costs based on the current loan market rate of 3.00% [8].

Summary of Key Points Core Viewpoint - The company intends to use part of the temporarily idle raised funds to supplement its working capital, which is deemed necessary for improving fund utilization efficiency and reducing financial costs [2][6][9]. Group 1: Fundraising Overview - The company issued 13,794,971 convertible bonds at a face value of 100 RMB each, raising a total of 1,379,497,100 RMB, with a net amount of 1,357,031,302.96 RMB after deducting underwriting fees [2][3]. - The funds are stored in a dedicated account as per the regulatory requirements, and a tripartite supervision agreement has been signed [3][4]. Group 2: Fund Utilization Plan - Originally, the raised funds were planned for specific projects, including the development of natural gas resources in the Shilou West Block, with a total investment of 137,949.71 million RMB [3][4]. - The company has proposed to use up to 40,000 million RMB of temporarily idle funds to supplement working capital, with a usage period not exceeding 12 months [5][6]. Group 3: Financial Efficiency - The company operates in a capital-intensive industry, necessitating the use of various financing sources, including loans, to support its operations [6][7]. - By utilizing idle funds for working capital, the company expects to save approximately 3.00% in financial costs based on current loan market rates [6][7]. Group 4: Internal Decision-Making Process - The board of directors and the supervisory board have approved the use of idle funds, confirming that the necessary internal procedures were followed [7][9]. - The funds can be used in a rolling manner within the approved limits and timeframe, ensuring that they will be returned to the dedicated account as needed [7][9].

Group 1 - The sixth session of the Supervisory Board of Nanjing Baose Co., Ltd. held its tenth meeting on June 13, 2025, via communication methods, with all five supervisors present [1][2]. - The Supervisory Board approved the temporary use of up to 200 million yuan of idle raised funds to supplement working capital, which is expected to meet the company's daily operational funding needs and reduce financial expenses [1][2]. - The decision to use part of the idle raised funds does not conflict with the implementation plan of the investment projects funded by the raised capital and is in the interest of the company and all shareholders [1][2]. Group 2 - The voting results of the meeting were unanimous, with 5 votes in favor, 0 against, and 0 abstentions [2]. - The announcement regarding the use of idle raised funds was also published on the designated information disclosure website of the China Securities Regulatory Commission [2]. - The meeting and its resolutions complied with relevant regulations, ensuring legality and effectiveness [1].

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].